Anoro Ellipta costs roughly $485 for a single 30-day inhaler without insurance, and the price isn’t expected to drop significantly anytime soon. The high cost comes down to a combination of patent protection that blocks generic competition until at least 2030, a proprietary inhaler device that’s difficult to replicate, and a drug pricing system where middlemen negotiate behind closed doors.
No Generic Competition Until 2030
The single biggest reason Anoro Ellipta remains expensive is that no generic version exists. GlaxoSmithKline holds patents on both the drug formulation and the Ellipta delivery device, with the last device patent not expiring until October 2030 and the last drug patent expiring in November 2030. Until those patents lapse, no competing manufacturer can legally produce a generic equivalent.
This is a common pattern with brand-name inhalers. As of 2021, only three inhaled medications in the U.S. had faced any generic competition at all: Advair Diskus, ProAir HFA, and Proventil HFA. The overwhelming majority of branded inhalers, including all the newer combination products for COPD, remain protected. That means the manufacturer can set the price without pressure from cheaper alternatives, and patients have no lower-cost option with the same active ingredients.
The Inhaler Device Is Hard to Copy
Anoro Ellipta isn’t just a medication. It’s a medication packaged inside a highly engineered delivery system, and that device is a major part of what keeps generics off the market. The Ellipta inhaler is assembled from 25 separate plastic components and two stainless steel springs. When you open the mouthpiece cover, a single mechanical action simultaneously advances a new dose, peels back a foil seal, collects the used foil, updates the dose counter, and produces an audible click to confirm activation.
For combination products like Anoro, the device uses a two-strip configuration: two separate blister strips containing different drug formulations sit inside the inhaler and deliver both drugs at once during a single inhalation. Each blister is individually sealed in foil laminate to protect the powdered medication from moisture and degradation over the full 30-day supply. This level of complexity means that even after the patents expire, a generic manufacturer would need to either replicate the device precisely or develop an entirely new one that delivers the same drugs with equivalent performance. Both paths are expensive and time-consuming, which is why generic inhalers take longer to reach the market than generic pills.
How PBMs Influence What You Pay
The price you see at the pharmacy counter is shaped heavily by pharmacy benefit managers, the companies that sit between drug manufacturers, insurance plans, and pharmacies. PBMs negotiate rebates from manufacturers in exchange for placing a drug on a plan’s preferred formulary. A preferred placement means lower copays for patients and more prescriptions filled, so manufacturers are willing to pay significant rebates to secure it.
The problem is that PBMs are not required to publicly disclose how much of a manufacturer’s rebate they keep for themselves versus how much they pass along to the insurance plan. This lack of transparency means the list price of a drug like Anoro can stay high (since the manufacturer offsets it with rebates), while patients, especially those who are uninsured or in high-deductible plans, get stuck paying based on that inflated list price. PBMs also decide which drugs require prior authorization and which land on less favorable formulary tiers, directly controlling how much a given patient pays out of pocket.
If Anoro lands on a non-preferred tier in your plan, you could face a significantly higher copay than someone on a different plan where PBM negotiations placed it more favorably. The same drug, at the same pharmacy, can cost wildly different amounts depending on who your insurer hired to manage prescriptions.
How Anoro Compares to Other COPD Inhalers
Anoro Ellipta belongs to a class of combination inhalers that pair two types of long-acting bronchodilators. Several competitors exist in this space, including Stiolto Respimat (tiotropium/olodaterol). None of them are cheap. Annual pharmacy costs for patients on Anoro averaged around $3,770 in one large claims analysis, compared to roughly $3,570 for patients on tiotropium/olodaterol. That’s a difference of about 5%, which is modest but adds up over years of daily use.
Beyond pharmacy costs, the same study found that Anoro users had higher COPD-related emergency department costs ($345 per year vs. $285 for tiotropium/olodaterol users) and higher outpatient costs. These differences likely reflect prescribing patterns and patient populations rather than drug quality, but they highlight that the total cost of managing COPD extends well beyond the inhaler itself.
Options for Reducing Your Cost
If you’re paying full price for Anoro Ellipta, a few strategies can bring the number down. GlaxoSmithKline offers a savings card for eligible commercially insured patients that can reduce copays. Pharmacy discount tools and coupon aggregators sometimes offer prices below the standard retail cost, though savings vary by location.
Switching to a different combination inhaler in the same drug class is worth discussing with your prescriber. Because PBMs negotiate different rebates for different products, a competitor inhaler might sit on a more favorable formulary tier in your specific plan, resulting in a lower copay for a clinically similar medication. The drugs in this class work through the same mechanisms, so for many patients, the choice between them comes down to cost, device preference, and insurance coverage rather than a meaningful difference in effectiveness.
For uninsured patients, manufacturer patient assistance programs and state pharmaceutical assistance programs can sometimes provide the medication at no cost or at a steep discount. These programs typically have income eligibility requirements, but the thresholds are higher than many people expect.